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SEROPREVALENCE OF HEPATITIS B, HEPATITIS C & SYPHILIS 
AND LIVER ENZYMES LEVELS IN HIV POSITIVE PATIENTS 
ATTENDING STD CLINIC 
 
ABSTRACT 
 
OBJECTIVES AND AIMS OF THE STUDY: 
 To detect the Prevalence of Hepatitis B, Hepatitis C and Syphilis and detection 
of Liver enzymes levels in HIV positive patients and thereby to establish the link of 
Liver enzyme levels by LFT in Hepatitis infection and HIV positive patients and also 
in patients who are VDRL reactive and HIV positive. 
 
MATERIALS AND METHODS: 
 100 cases of HIV positive patients attending the STI Out Patient detected by 
Rapid Assay(immunoblot assay)kit would be selected for this study.  
 
 Detailed clinical history (including H/O of presenting complaints, occupational 
history, menstrual history, marital history, sexual history/ last H/o contact, obstetric 
history, past H/o sexually transmittedinfections) followed by thorough clinical 
evaluation would be done. 5 ml blood is withdrawn aseptically from the patient. The 
serum is separated and subjected to Rapid Assay test for the detection of HIV and then 
HIV positive blood samples are subjected to VDRL, HBsAg, anti-HCV,.and 
LFT.VDRL reactives will be subjected to TPHA test. 10 patients who are HIV 
negative are taken as controls 
 
RESULTS: 
 In our study, HIV-HBV co-infection was seen in 13(13%) patients, HIV-HCV 
co-infection was seen in 1(1%) patient, HIV with Syphilis co-infection was seen in 
2(2%) patients, Elevated liver enzyme levels in HIV positive patients were seen in 
4(4%) patients, Decreased CD4 count was seen seen in 3(3%) patients, HIV-HBV co-
infection with elevated liver enzyme levels and decreased CD4 count was seen in 
3(3%) patients, HIV-HCV co-infection with elevated liver enzyme levels and 
decreased CD4 count was seen in 1(1%) patient, HIV-HBV-HCV co-infection with 
elevated liver enzyme levels and decreased CD4 count was seen in 1(1%) patient 
 
CONCLUSION 
 Thus to conclude, The decreased CD4 count with elevated liver enzyme levels 
as seen in our study will cause further liver damage, hence ART should be 
immediately started in these patients. Hence routine screening for Hepatitis B and 
Hepatitis C should be emphasized in HIV positive patients since its early detection 
can decrease the morbidity and mortality due to liver damage among these patients 
and screening for Syphilis should also be encouraged in HIV positive patients since its 
early detection can decrease the morbidity and mortality among these patients. By  
routine screening effective treatment can be implemented to increase the life span and 
quality of life among such patients . 
 
KEYWORDS:  
 Human Immunodeficiency Virus, Hepatitis B, Hepatitis C , Syphilis, elevated 
Liver enzymes, CD4 count. 
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INTRODUCTION 
 
 HIV the retro virus is the etiological agent of AIDS which is a late 
clinical manifestation of infection with HIV1.It is important to know 
about HIV disease because if not treated on time it progresses relentlessly 
and leads to death over a period of about 10years2.The credit of detecting 
the first case of HIV in India goes to Tamil Nadu state which was in 
1986, but worldwide HIV was discovered a little earlier around 1981 in 
South Africa. Robert Gallo3 and French scientist Professor Montagnier4 
in 1983 were the first to isolate the causative agent for HIV. There are 
two main types of HIV among which HIV 1 is thought to originate from a 
Simian immunodeficiency virus from chimpanzees and HIV2 from Sooty 
Mangabey Monkey.5 
 
 HIV is associated with a number of viral disease which are 
transmitted through similar routes of transmission like that of HIV which 
may include Hepatitis B, and Hepatitis C. Viral Hepatitis is the primary 
infection of liver which is caused by a heterogenous group of Hepatitis 
viruses namely A, B, C , D,E6.Out of these Hepatitis B is mainly 
important and according to WHO it accounts for about one million deaths 
worldwide every year.HBV is primarily blood borne infection which is 
transmitted by parenteral, perinatal and sexual modes but is also excreted 
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in saliva, breast milk, urine, bile, faeces, semen and vaginal secretions, 
among these saliva and semen are well known to transmit HBV 
infection7.Hepatitis C is epidemiologically similar to Hepatitis B and is 
known to occur only in humans. It is mainly transmitted by blood 
transfusion, injection drug abusers, immunocompromised and transplant 
recipients are at major risk and accounts for one quarter of chronic 
Hepatitis in India.9 Thus although Hepatitis B and Hepatitis C are mainly 
transmitted through blood transfusion and blood products, sexual 
transmission is also known to occur though this mode of infection is low 
and have become epidemiologically important from the heterosexual 
transmission  point of HIV. 
 
 Syphilis is an infectious disease caused by Treponema Pallidum 
which belongs to the order Spirochaetals and family Spirochaetacea 
which has a chronic course and capacity to affect any structure of the 
body, which may show florid manifestation or might remain 
asymptomatic for many years and it also resembles many disease in 
medicine or surgery fields, apart from  transmission to offspring its 
transmission to laboratory animals can also occur which can be treated to 
the extent of presumptive cure14. 
 
 Syphilis is complexly related to HIV infection, there are many 
documental studies stating that Sexually Transmitted Infection’s (STIs) 
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like Syphilis are thought to raise the risk of HIV infection among the 
individuals of homosexuals and also heterosexuals.15,16 Hepatobiliary 
system is somehow uniquely related to retroviral infection and viral 
hepatitis and Syphilis. Liver enzymes are variably elevated in HIV 
infected individuals which was more prevalent prior to the invent of 
HAART(Highly Active Antiretro Viral Therapy),but now apart from 
ART, increase in liver enzyme is associated to the underlying primary 
liver pathology, alcohol and also to viral Hepatitis.19Thus abnormal liver 
enzyme in HIV disease can present with a wide range of manifestation 
from mild steatohepatitis to the extremes of liver fibrosis hence its early 
detection helps to asses the prognosis in such retroviral infection,20but it 
should also be beared in mind that it is possible for HIV patients to show 
elevated liver enzymes even in the absence of  Hepatitis.21 
 
 Unlike HIV, liver enzymes are not significantly elevated in 
Syphilis, but there are literature stating the occurence of Syphilitic 
hepatitis  in HIV infected patients.22-25Early sign to detect  the co-
exsistance of syphilitic hepatitis are, the patient presents with perianal 
lesion and disproportionate elevation in liver enzyme levels.26 
 
Review of Literature 
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REVIEW OF LITERATURE 
 
STRUCTURE OF HUMAN IMMUNODEFICENCY VIRUS (HIV) 
 Hockley27 and Gelderblomet at 28 have contributed for their 
discovery of HIV structure.It is a spherical shaped retrovirus which 
encloses a nucleocapsid which is roughly bullet shaped which contains 
three different enzymes reverse transcriptase,integrase and protease and a 
single standard RNA. A lipid envelope surrounds the viral core,these 
envelope bears raised spike like projection called gp160,which inturn 
consists of cap like projection called gp120 . 
 
Figure 1:  HIV structure 
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REPLICATION CYCLE OF HIV 
 HIV is a retrovirus which is unique in a way that it replicates only 
in human cells . 
The principle steps in the beginning of HIV replication are  
1. The viral entry into target cell which occurs by facilitating the binding 
of gp120(envelope glycoprotein) of the virus to a unique 
receptor(CD4) 
↓ 
2. A process of conformational change exposes gp41(fusion peptide) 
which favours  the intimate fusion of virus with cell surface membrane 
↓ 
3. This fusion is followed by reverse transcription which occurs in the  
viral nucleoprotein, where it generates a single DNA copy from the 
viral genome , this step is accomplished by the help of enzymes, 
reverse transcriptase 
↓ 
4. Integrase enzyme  is the  one that facilitates the complex integration of 
viral particle into the chromosomal DNA of host cell which forms the 
‘provirus’ . 
↓ 
5. viral protein expression takes place by the collaborative action of 
RNA polymerase, transcription factor and also by certain regulatory 
proteins(tat, rev). 
↓ 
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6. Assembly of core enzymes of HIV and RNA takes place but they are 
still immature due to the lack of envelope protein which are 
synthesized in the specialized organelles of endoplasmic reticulum of 
the infected cells, by this way viral envelope protein is expressed on to 
the surface of cell 
↓ 
7. The process of replication ends when the enzyme protease cleaves 
certain proteins like gag, gag-pol so that the virion matures and the 
matured virion are now ready to restart a new cycle.      
 
ROUTES OF TRANSMISSION 
 Venereal (semen, vaginal and cervical discharge ) and blood 
tansfusion,29 are the two main modes of HIV transmission, but the virus 
can also make entry into the body through following ways : 
 Breast milk30 
 Saliva30 
 Colostrum30 
 Urine30 
 Tears30 
 Presence of genital ulcer extends the risk of retroviral  
transmission31 
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 HIV transmission are also known to occur through artificial 
insemination32 
 Vertical transmission becomes greater during 3rd trimester or at the 
time of delivery33 
 Anticipation of infected mother transmitting the infection to new 
born is about 20% to 50%34,35 
 Blood donation from high risk group are not reliable since the 
patient might be in window period(3-17weeks) or the result can 
also be false negative.36,37 
 The possibility of transmission through needle stick injury in health 
care workers is about 0.5%38 
 
PATHOGENESIS 
 The retro virus enters the human body via the mucosal surface like 
the, genital mucosa, oropharynx, rectum primarily by sexual contact and 
since these mucosal surface are rich in langerhans cells and dendritic cells 
they trap the antigen and virus particles which replicates rapidly and 
subsequently establishes primary viraemia by then a huge number of 
infected cells in peripheral blood and high titres of virus  of  upto several 
million virus particles per ml of blood can be detected.39 
 
 This response is followed by significantly huge fall  in the number 
of CD4 cells, and an associated activation of CD8+ T cells, which  is 
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known to kill virus infected cells, and subsequently produce 
seroconversion. This CD8+ T cell  plays an important role in controlling 
virus level. This is followed by a clincal latent period which may last for 
several years. The exact mechanism how HIV destroys CD4+ T cells is 
quite unexplained and complex40 
 
The possible known mechanism  are: 
Direct cell killing 
 When large number of viruses are produced and burst out from cell 
surface theymay directly kill infected CD4+ Tcells. 
 
Syncytia formation 
 The infected CD4+ T cells are known to fuse with neighbouring 
uninfected cells to form ballon like large cells called syncytia. 
 
Apoptosis 
 The infected CD4+ cells may also be killed by programmed cell 
death called apoptosis which can occur either in blood stream or lymph 
node. 
 
 Eventhough new T cells are persistently being produced by 
the thymus for the replacement of the lost old ones, the regenerative 
ability of the thymus is  being slowly destroyed by direct infection of  
thymocytes by  the retro virus, ultimately even the low number of CD4+ T 
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cells required to maintain the proper immune system is lost, leading to 
full blown AIDS. 
 
CLINCAL MANIFESTATION 
Clinical features of HIV can be grouped into the following stages 
1. Primary HIV infection 
2. Asymptomatic stage 
3. Early symptomatic stage 
4. Latesymptomatic stage 
5. Advanced HIV disease. 
 
1. Primary HIV infection 
 It usually occurs in 50 to 90% patients around 2 to 4weeks after the 
viral exposure and may present with features resembling infectious 
mononucleosis like pharyngitis, fever, lymphadenopathy, maculopapular 
rash, head ache nausea, vomiting, myalgia42,oral ulcer, arthalgia42, 
diarrhoea, neurological features – radiculopathy, meningoencephalitis, 
peripheral neuropathy, and psychosis. 
 
2.Asymptomatic stage 
 Primary HIV infection is followed by an asymptomatic stage 
during which the patient is symptomless except some patient can present 
with persistent generalised lymphadenopathy. 
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3. Early symptomatic stage 
a) Constitutional symptoms are present initially like fatigue, fever, 
unexplained weight loss, recurrent diarrhoea. 
b)  Cutaneous features: 
(i)  Infectious manifestation: 
 Oral candidiasis 
 Molluscum contagiosum41 
 Oral  hairyleukoplakia 
 Wart 
 Dermatophytosis43 
 Herpes zoster43 
 Herpes simplex virus infection43 
 
(ii) Non infectious manifestation: 
 Psoriasis vulgaris46 
 Reiters syndrome  
 Seborrhoeic dermatitis 
 Pruritic papular dermatitis 
 Vitilligo48 
 Pitryriasis rubra pilaris49 
 Photodermatitis47 
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 Granuloma annulare48 
 Nail changes-leuconychia, onychomycosis, paronychia 
 
c) Respiratory features include - Pulmonary tuberculosis, haemophilus 
influenza, streptococcus pneumonia and mycoplasma pneumonia 
d) Haematological features-anemia45, thrombocytopenia , neutropenia 
e) Renal manifestation - glomerulonephritis, HIV associated 
nephropathy and nephrotic syndrome. 
 
4. Late symptomatic stage 
 A drop in the CD4 count triggers opportunistic infections like 
pneumocystis carinii pneumonia(PCP), mycobacterium avium complex, 
toxoplasmosis, oesophageal candidiasis. 
 
5. Advanced HIV disease 
 This includes malignancies like kaposi’s sarcoma, lymphoma, Non 
Hodgkins Lymphoma(NHL)44, among these kaposi’s sarcoma was 
supposed to be the first and most common neoplasm occurring in HIV 
disease. Other opportunistic infection reported to occur in advanced HIV 
disease are CMV infection, cryptococcal meningitis, histoplasmosis and 
AIDS wasting syndrome. 
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Laboratory diagnosis of HIV 
1.Detection of HIV specific antibodies in plasma/serum by the following 
test 
A) Screening test which primarily include 
 ELISA 
 
ELISA are of four main type 
i. Indirect ELISA 
ii. Sandwich ELISA 
iii. Competitive ELISA 
iv. Antigen-Antibody capture ELISA 
 Rapid test for HIV  
 
B) Supplemental tests which include 
 Western blot test 
 Immunofluorescence assay 
 Line immune assay 
2. Detection of HIV specific antibodies in body fluids like saliva 
3. Detection of HIV specific antibodies in patients urine 
4. Confirmatory test 
a. Polymerase Chain Reaction(PCR) 
b. Virus isolation 
c. Test for detection core antigen (P24) 
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Figure 2: ELISA plate 
 
 
 
 
Figure 3:INDIRECT  ELISA 
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Figure 4:SANDWITCH  ELISA 
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WHO guidelines for starting ART based on clinical staging and CD4 
count 
Clinical staging Recommendation 
Clinical stage I and II 
ART started if CD4 count 
is<350cells/mm3 
Clinical stage III and IV 
ART started irrespective of CD4 
count 
For HIV patients co-infected with Hepatitis B and Hepatitis C 
infection  
HIV-HBV,HIV-HCV co-infection 
in the absence of chronic active 
Hepatitis 
ART started if CD4 count 
is<350cells/mm3 
HIV-HBV,HIV-HCV co-infection 
in the presence of chronic active 
Hepatitis 
ART started irrespective of CD4 
count 
For HIV patients co-infected with Tuberculosis 
HIV-TB (pulmonary   or 
extrapulmonary) co-infected 
patients. 
ATT must be started immediately 
and ART can be added between 2 
weeks to 2 months or as early as 
possible when TB treatment is 
tolerated  
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Syphilis 
Morphology  
 Treponema Pallidum the causative agent of Syphilis is a regular 
spiral shaped, coiled, slender, organism. The length may vary from 6 to 
10 micro meter  and width 0.25micro meter. It is better appreciated 
through dark ground microscope than light microscope due to its narrow 
morphology and low content of protoplasm .This organism reproduces by 
binary fission and shows a wide range of movements(motility) ranging 
from angulation, rotation, buckling, propulsion, expansion, undulation to 
coil compression. 
 
Figure 4: Dark ground microscopic appearance of 
treponemapallidum 
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CLASSIFICATION OF SYPHILIS  
 
 
ROUTES OF TRANSMISSION 
1. The primary mode by which T.pallidum is transmitted by sexual 
contact. Although majority population practice heterosexual 
method , oral sexual contact is emerging as an important mode in 
MSM. 
2. Vertical transmission 
3. Needle prick injury in health workers 
4. Breast feeding in the presence of infected lesion on breast  
5. Kissing50 
6. Syphilis brephotrophica51 – Syphilis transmitted to persons , while 
taking care of  babies  
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PATHOGENESIS 
 The organism enters human tissue under favourable conditions 
via minor abrasion, through sexual contact after which they reach 
bloodstream and lymphatics as early as few hours after inoculation,52 
where they multiply and rapidly disseminate to other regions. Once 
multiplication has reached required density, it elicits a local reaction to 
form chancre , which resolves spontaneously without even treatment by 3 
to 8 weeks. After a period of about 2 to 12 weeks features of secondary 
Syphilis appears which may also heal without treatment in about 2 to 12 
weeks. The patient soon enters a asymptomatic period of early latent 
Syphilis (< 1years) and late latent Syphilis (> 2years). One third of 
patients after a quiet long time may manifest with features of 
cardiovascular Syphilis (by 10 – 40 years) and neuro Syphilis (by 3 – 35 
years) 
 
CLINICAL FEATURES 
Primary syphilis 
 The characterstic feature is Hunterian chancre which is usually a 
solitary well defined ulcer, round to oval in shape with a button like 
induration, rolled out edges and floor may be covered with greyish slough 
or rarely with haemorrhagic slough. It appears after about 3 to 90 days of 
exposure to organism and the most common site in males is coronal 
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sulcus followed by glans penis and in females vagina and cervix. Extra 
genital sites include breast , lips, finger and anorectal sites. Various types 
of chancre are condom chancre , chancre redux(infectious), 
pseudochancre redux (non infectious) and Syphilis d emblee, phagedenic 
chancre, and chancre gallius. 
 
Secondary Syphilis 
 It presents with a wide range of polymorphic lesion ranging from 
macule, papule, pustule to papulosquamous lesion. 
 
 Macular syphilide–appears as pinkish rounded discrete lesion 
most common on chest, shoulder, and back. 
 
 Papularsyphilide – is the characterstic lesion of  Secondary 
Syphilis it is less than 1cm in size and symmetrically distributed on trunk, 
arms, face, and extremities other forms of papularsyphilide include 
corona veneris, condylomatalata , annular syphilide , follicularsyphilide 
(moth eaten alopecia). 
 
 Papulosquamoussyphilide – papules covered with predominant 
scales resembling psoriasiform lesion. 
 
 Pustularsyphilide - occurs  rarely seen in debilitating patients. 
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Mucous membrane involvement 
 Oral mucosa – commonly affected sites are mucosa of lip , 
tongue , pharynx , tonsil ,larynx . Snail track ulcer often appear on tonsil 
but may also involve other sites. 
 
 Genital mucosa – vulval and vaginal mucosa in females and glans 
penis mucosain males are commonly involved. 
 
 Luis maligna53,54 -  Luis maligna initially presents with 
constitutional symptoms like malaise, fever, arthalgia, headache and 
photophobia followed by a papulopustular lesion which undergoes 
necrosis and edges are sharply marginated with thickened rupoid crust. 
 
Late benign gumma 
 Late benign gumma typically presents with punched out ulcer 
covered with wash leather slough involving palms, soles, mucous 
membrane of palate, nasal septum, pharynx and also involves internal 
organs like liver and spleen. 
 
Cardiovascular Syphilis 
 With the effective antibiotic use the  patient reaching to 
cardiovascular Syphilis is becoming rare even in AID’s patient and when 
present it shows a vivid manifestation like myocarditis, aortic 
regurgitation, aortic aneurysm, coronary artery stenosis and aortitis. 
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Neurosyphilis 
 Neurosyphilis takes many decades of about 5-35 years for its 
clinical manifestation and the possible presentation include acute 
syphilitic meningitis, meningovascular Syphilis, in 10% of cases General 
Paresis of Insane(GPI) and rarely can present with tabesdorsalis. 
 
Laboratory diagnosis of Syphilis 
Primary Syphilis 
 Primary Syphilis is diagnosed mainly by microscopic 
examination of  T.pallidum through: 
a) Dark Field Microscopy (DFM) 
b) Direct Fluorescent Antibody-TreponemaPallidum (DFA-TP) 
 
 Serological test are not much reliable since the T. Pallidum can 
be detected only after a period of 1 to 4 weeks of chancre formation. 
 
Secondary Syphilis 
 Secondary Syphilisis diagnosed by serological tests with a 
sensitivity of 100% and they are of two types: 
 Non-Treponemal tests 
 Treponemal tests 
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 Non-Treponemal tests 
a)  VDRL 
 VDRL in a titre of  > 1:8 in a patient with first episode of Syphilis 
and a four fold elevated  titre in a patient with past history of Syphilis 
indicates a positive result. In cases of  patient showing < 1:8 titre, the test 
should be repeated after a period of 10 weeks or confirmed by a 
Treponemal test. 
 
b) Rapid Plasma Reagin (RPR) test 
 This test uses cards unlike the slides used inVDRL test and a 
modifiacation of  this test is called TRUST ( toludine red unheated serum 
test ) 
 
 Treponemal tests 
a) Fluorescent Treponemal antibody absorption test (FTA-Abs) 
b) Treponemapallidum immobilization test (TPI) 
c) Treponemapallidumhaemagglutination test (TPHA) 
d) Microhaemagglutination test for Treponemapallidum (MHA-TP) 
 
23 
 
Latent Syphilis 
 Since the lesions are absent during this stage definite  diagnosis  is 
quiet difficult early latent Syphilis is diagnosed by Non-Treponemal tests 
however in late latent Syphilis Non-Treponemal tests are negative in 30% 
cases and such patients results should be confirmed by Treponemal tests. 
 
Tertiary Syphilis 
 Treponemal tests are test are used to diagnose this stage but around 
2 to 4% of patients show reports with Treponemal tests and such patients 
may require other test like PCR. 
 
Neurosyphilis 
 The VDRL-CSF test is considered to be the standard serologic test 
for neurosyphilis and when reactive in the absence of contamination of 
the CSF with blood, it is considered diagnostic of neurosyphilis. 
 
Congenital Syphilis 
 Congenital Syphilis can be diagnosed by isolation of T. Pallidum 
from the nasal discharge or from the umbilical vein blood, but these are 
not confirmatory test since it can be due to transfer of maternal 
antibodies.  
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Hence the diagnostic test  include: 
a) FTA-ABS test using fluorescent-labelled anti-human globulin. 
b) PCR from cerebrospinal fluid. 
 
Treatment of Syphilis 
1. Primary and early latent Syphilis 
 Injection benzathine penicillin G 2.4 million units given 
intramuscularly  in a single dose with 1.2million units into each gluteal 
region.  
 
 In patients allergic to penicillin alternatively the following drugs 
can be given 
c) Capsule doxycycline 100 mg orally twice daily for 14 days, or 
d) Capsule tetracycline 500 mg orally 4 times daily for 14 day 
 
2. Late latent Syphilis,Gumma and cardiovascular Syphilis 
 Injection benzathine penicillin G 7.2 million units total, which is 
administered as 3 doses of 2.4 million units intramuscularly each at 3-
week intervals. 
 
 In patients allergic to penicillin alternatively the following drugs 
can be given. 
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a) Capsule doxycycline 100 mg orally twice daily for 30 days OR 
b) Capsule tetracycline 500 mg orally 4 times daily for 30 days. 
 
3.Neurosyphilis 
 Injection aqueous crystalline penicillin G 18-24 million units per 
day, administered as 3-4 million units IV every 4 hours or by continuous 
infusion for 10-14 days given intravenously . 
 
 In patients allergic to penicillin alternatively the following drugs 
can be given Injection procaine penicillin 2.4 million units IM once daily 
along with tablet Probenecid 500 mg orally 4 times a day, both given for 
10-14 days. 
 
4. Congenital Syphilis 
 Injection aqueous crystalline penicillin G 1 to 1.5 lakh units/kg/day 
given in a divided dose 50,000units/kg/dose through intravenous route for 
every 12 hours for the intial 7 days which is then given 8th hourly for a 
total period of 10 days. Alternatively injection procaine penicillin 
50,000units/kg/dose intramuscularly once daily for 10 days can be given. 
 
Hepatitis B and Hepatitis C 
 Among the viral causes of  infectious Hepatitis, most common and  
major health problems are Hepatitis B and Hepatitis C. Greater  than one 
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third population in the world are documented to be Hepatitis B and 
Hepatitis C infected. Though HBV(double stranded DNA virus) and 
HCV(single stranded RNA virus) are structurally different they share 
similar routes of transmission and clinical presentation. 
 
Routes of transmission 
 Hepatitis B and Hepatitis C are predominately transmitted through 
blood transfusion and blood products55 other possible modes of  
transmission include 
 Venereal route56 
 Vertical transmission57 
 Intravenous drug abuse58 
 Infected needles and syringes59 
 Saliva60 
 Tatooing61 
 
Clinical features 
 Incubation period of Hepatitis B vary from 1 to 6 months  
compared to 15 to 150 days of Hepatitis C. Clinically both HBV and 
HCV  intially presents with constitutional symptoms like fatigue, 
anorexia, malaise, myalgia, nausea vomiting, arthalgia, and less 
frequently they can present with headache, pharyngitis, cough, 
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photophobia and coryza 1 to 2 week before the onset of jaundice. These 
prodromal features reduces with onset of  jaundice. 
 
 During the icteric phase patients can present with upper abdominal 
pain due to liver  and spleen enlargement, cervical lymphadenopathy. 
Acute Hepatitis B infection in 90-95% normally recovers within 1-2 
months whereas about 1-10% of cases remain chronically infected and 
can go for cirrhosis or persist as chronic liver disease.8Similarly Hepatitis 
C in 1% cases  can enter into phase of  fulminant Hepatitis or progress to 
hepatocellular carcinoma. 
 
Figure 5: Various antigens and antibodies demonstrable in HBV 
infection
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Figure 6 : HBsAg ELISA plate showing  
positive and negative controls 
 
 
 
Figure 7:HBsAg positive by card test method 
 
Aims & Objectives 
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AIMS & OBJECTIVES 
 
1. To detect the Prevalence of Hepatitis B, Hepatitis C and Syphilis and 
Detection of Liver enzymes levels in HIV positive patients. 
2. To establish the link of Liver enzyme levels by LFT in Hepatitis 
infection and HIV positive patients. 
3. To study the Liver enzymes levels in patients who are VDRL reactive 
and HIV positive.  
 
Materials and Methods 
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MATERIALS & METHODS 
 
STUDY DESIGN 
 Prospective Observational study 
 
STUDY GROUP 
 100 HIV positivepatients attending the STI Out Patient 
Department, Institute of  Venereology, Madras Medical College / 
RGGGH, Chennai are selected randomly. 
 
 The Institute ethics committee clearance was obtained and 
informed consent was taken from all the patients included in study group. 
 
INCLUSION CRITERIA 
 All HIV positive patients attending STI Out Patient Department 
with High Risk like: 
1. Female sex workers 
2. Partners of HIV seropositive / VDRL reactive patients 
3. Transgenders 
4. Homosexuals  
5. Victims of sexual abuse 
6. Intravenous drug abusers 
7. H/o multiple blood transfusions 
8. Occupational exposure to blood products  
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EXCLUSION CRITERIA 
1. Patients who refuse to participate in the study 
2. Children and Patients above 60 years 
 
PROCEDURE 
 A detailed and thorough history was obtained pertaining to the 
following parameters: 
 
 Age 
 Occupation 
 Socioeconomic status 
 Marital and obstetric history 
 Sexual history 
 History  of blood transfusion 
 History related to sexually transmitted infections as per the 
proforma enclosed. 
 Past, Personal, Treatment history shall be documented along with 
clinical examination. 
 
 Under aseptic precautions, about 5ml of blood is withdrawn from a 
vein and centrifuged by 2500 RPM to separate the serum, the sample is 
then tested for HIV by Rapid test (dot immunoassay) kit, wherein the 
immobilized antigen-antibody complex is visualized by means of colour 
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producing (chromogenic) reaction. The coloured endpoint is developed 
by Colloidal Gold –Protein –A Signal Reagent.10 patients’ blood samples 
who are HIV negative was taken as controls.  
 
HIV positive blood samples are then subjected to: 
1. VDRL test  
 The centrifuged serum is inactivated by keeping in hot water bath 
for 30min at 56oC the test is usually carried out qualitatively and if 
qualitative test shows positivity it is subjected to quantitative test. 
 
Qualitative test 
 In qualitative test 0.05ml of serum is added to one drop of antigen. 
The mixture is then rotated for 4min at 180RPM in a VDRL rotator, 
along with this positive and negative control samples will be tested, the 
wells are then observed through microscope to detect any flocculation 
reaction and reported as follows: 
 
1. No clumps or slight roughness-Non Reactive 
2. Small clumps-Weakly positive 
3. Medium and large clumps- Reactive 
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Quantitative test 
 Reactive cases are then subjected to quantitative test which is done 
by slide flocculation or tube flocculation test. 
 
Slide flocculation test: 
 0.5ml of normal saline is pipetted out in each well of slide starting 
from 2nd well. 
 In well 1, 0.5ml of undiluted serum is taken 
 0.5ml of test serum is pipetted out in well in 1:2 dilution 
 0.5ml from well 2 is taken and added to well 3, like this1:4 dilution 
continued upto 1:64 
 Positive and negative controls for each test is incorporated 
 1 drop of viral antigen is added to each ring with 18 gauge needle 
 The wells are then rotated for 4min at 180RPM and seen under 
microscope and the highest dilution that has flocculation is 
reported reactive titre.  
 
2. HBsAg detection using HEPALISA kit 
 HEPALISA is a solid phase enzyme linked immunosorbentassay 
(ELISA) it is based on the ‘’Direct Sandwich’’ principle.  
 
 Here the microwells are coated with monoclonal antibodies with 
high reactivity for HBsAg.The samples are added in the wells followed 
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by addition of enzyme conjugate linked to Horseradish 
Peroxidase(HPRO).A sandwich complex is formed in the well wherein 
HBsAg (from serum sample) is ‘’trapped’’ or ‘’sandwiched’’ between the 
antigen and antibody HPRO conjugate. Unbound conjugate is then 
washed off with wash buffer. The amount of bound peroxidase is 
proportional to the concentration of  HBsAg present in the sample. 
 
 Upon addition of substrate buffer and chromogen, a blue colour 
develops. The intensity of blue colour developed is proportional to the 
concentration of HBsAg in sample.To limit the enzyme-substrate 
reaction, stop solution(sulfuric acid) is added and a yellow colour 
develops which is finally read at 450nm spectrophotometrically. 
 
Figure 8: Contents of  HEPALISA kit 
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3. Detection of anti-HCV antibody by using 3rdgeneration HCV 
Microlisa kit 
 Diluted sample and controls are incubated for 30min.Antibodies to 
HCV, if present, bind to immobilized HCV antigens on the microwell. 
 
 The micro wells are then thoroughly washed with the diluted wash 
buffer to remove excess of unbound anti-HCV or other human IgGs 
which may interfere with the test. An enzyme conjugate anti-human IgG 
conjugated with HPRO is added. 
 
 The enzyme substrate reaction leads to development of blue colour 
which is indicative of Ag-Ab reaction.Finally, the stop solution is added 
and the optical density of the developed colour is read photometrically. 
 
Figure 9: Contents of  HCV microlisa kit 
 
Observation and Results 
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OBSERVATION AND RESULTS 
 
SEX DISTRIBUTION OF HIV POSITIVE PATIENTS 
 100 HIV positive patients fulfilling the inclusion criteria were 
enrolled in the study . 
 
 Out of these 100 patients, 70(70%) were males and 30(30%) were 
females. Thus, HIV infection was more common in males than females  
with male:female ratio as 7:3. 
 
Table 1 : SEX DISTRIBUTION (N=100) 
 
 
 
Figure 1 : SEX DISTRIBUTION 
 
MALE FEMALE 
70 30 
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AGE DISTRIBUTION OF HIV POSITIVE PATIENTS 
 
 The age of the patients ranged from 20 to 80 years. The most 
commonly affected age group was 31 – 40 years with 33 (33%) patients, 
closely followed by 20-30 years age group with 28 (28%) patients . 
 
       Thus HIV infection was most common in the age group of   
31-40years. 
 
Table 2: AGE DISTRIBUTION 
 
AGE n=100 
20-30 28 
31-40 33 
41-50 23 
51-60 10 
61-70 4 
71-80 2 
TOTAL 100 
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Figure:2 AGE DISTRIBUTION OF HIV POSITIVE PATIENTS 
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SEX WISE AGE DISTRIBUTION OF HIV POSITIVE PATIENTS 
 
 Maximum number of affected males were in the age group of 31-
40years With 22 (34.1%) males in this group . 
 
 It was followed by 20-30 years with 18(25.7%) males and 41 to 50 
years with 18(25.7%) males  respectively.  
 
 Females were also affected more in the age group of  31to 40 years 
with a total of 11 (36.6%) women in this age group, followed by 41 to 50 
years group with 10 (33.3%) patients(Figure 11). 
 
Table 3: SEX WISE AGE DISTRIBUTION 
AGE MALE FEMALE 
20-30 18 10 
31-40 22 11 
41-50 18 5 
51-60 6 4 
61-70 4 0 
71-80 2 0 
TOTAL 70 30 
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Figure: 3 SEX WISE AGE DISTRIBUTION OF  
HIV POSITIVE PATIENTS 
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DISTRIBUTION OF ALCOHOLICS IN HIV POSITIVE 
PATIENTS 
 Out of the 70 male patients, 49(70%) were alcoholics and the most 
common affected age group were 20-30 years with 15(21.4%) patients 
followed by 31-40 years with 14(20%) patients. 
 
 
Table 4: DISTRIBUTION OF ALCOHOLICS IN  
HIV POSITIVE PATIENTS 
   
AGE n=49 
20-30 15 
31-40 14 
41-50 11 
51-60 5 
61-70 2 
71-80 2 
TOTAL 49 
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Figure 4: DISTRIBUTION OF ALCHOLICS IN  
HIV POSITIVE PATIENTS 
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DISTRIBUTION OF SMOKERS IN HIV POSITIVE PATIENTS  
 Among the 70 male patients, 48(68.5%) were smokers and the 
most common affected age group were 31-40 years with 13(18.5%) 
patients followed by 20-30years with 12(17.1%) patients. 
 
Table 5: DISTRIBUTION OF SMOKERS IN  
HIV POSITIVE PATIENTS 
 
 
 AGE n=48 
20-30 12 
31-40 13 
41-50 14 
51-60 5 
61-70 3 
71-80 1 
TOTAL 48 
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Figure 5: DISTRIBUTION OF SMOKERS IN  
HIV POSITIVE PATIENTS 
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MARITAL STATUS IN HIV POSITIVE PATIENTS 
 Out of 100 patients, 78 were married and among these the most 
common affected age group was 31-40 years with 25(25%) patients 
followed by 41-50 years with 2(23%) patients. 
 
Table 6: MARITAL STATUS IN HIV POSITIVE PATIENTS 
 
AGE MALE FEMALE TOTAL 
20-30 10 6 16 
31-40 16 9 25 
41-50 18 5 23 
51-60 5 4 9 
61-70 4 0 4 
71-80 1 0 1 
TOTAL 54 24 78 
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Figure 6: MARITAL STATUS IN HIV POSITIVE PATIENTS 
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ELEVATED LIVER ENZYME LEVELS IN HIV POSITIVE 
PATIENTS 
 Out of the 100 HIV positive  patients, liver enzyme was elevated in 
4(4%)  patients, among these, 3 patients showed elevated SGPT, SGOT 
and 4 patient showed elevated alkaline phosphatase with ; 
 
SGPT-  60 IU, 76 IU, and 120 IU   
SGOT-  80 IU, 68 IU and 94 IU and   
Alkaline phosphatase -133 IU, 140 IU, 166 IU and 140 IU   
 
Table 7: ELEVATED LIVER ENZYME LEVEL IN  
HIV POSITIVE PATIENTS 
  
  
AGE No of patients SGPT (0-40 IU) 
SGOT 
(0-45 IU) 
ALKP 
(30-120 IU) 
20-30 1 76 68 140 
31-40 1 120 94 166 
41-50 0 - - - 
51-60 1 - - 140 
61-70 1 60 80 133 
71-80 0 - - - 
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Figure 7: ELEVATED LIVER  ENZYME LEVEL IN  
HIV POSITIVE PATIENTS 
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Table 8 : OCCUPATION OF HIV POSITIVE PATIENTS  
 
 
 
 
OCCUPATION NO OF PATIENTS 
Manual labor 40 
Mason 7 
Auto driver 5 
Private company 5 
Electrician 4 
Truck driver 3 
Farmer 2 
Security 2 
Clerk 2 
Accountant 1 
Tailor 1 
Artist 1 
Real estate 1 
Gold smith 1 
Hotel worker 1 
Painter 1 
Office manager 1 
Mechanic 1 
House wife 16 
Student 5 
TOTAL 100 
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Figure 8: OCCUPATION OF HIV POSITIVE PATIENTS  
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LITERACY LEVEL IN HIV POSITIVE PATIENTS 
 Out of 100 patients, 34 were illiterate and the highest level of 
literacy among others were upto high school (33%) followed by primary 
school (26%). 
 
Table 9 : LITERACY LEVEL IN HIV POSITIVE PATIENTS 
 
EDUCATION MALE FEMALE TOTAL 
Primary school 20 6 26 
High school 26 7 33  
Higher secondary 
education 6 1 7 
Illiterate 18 16 34  
TOTAL 70 30 100 
 
 
Figure 9 : LITERACY LEVEL IN HIV POSITIVE PATIENTS 
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AGE DISTRIBUTION IN HBsAg POSITIVE HIV PATIENTS  
 Out of 13 HBsAg positive HIV patients, the maximum number of 
affected individuals belonged to 41 to 50 years with 5(38.6%) patients 
followed by 20 to 30 years with 4(30.7%) patients. 
 
Table 10: AGE DISTRIBUTION IN HBsAg  POSITIVE  HIV 
PATIENTS 
AGE n=13 
20-30 4 
31-40 1 
41-50 5 
51-60 2 
61-70 1 
71-80 0 
TOTAL 13 
 
 
Figure 10: AGE DISTRIBUTION IN HBsAg POSITIVE HIV  
PATIENTS 
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SEX DISTRIBUTION IN HBsAg POSITIVE HIV PATIENTS 
 Out of 13 HBsAg positive HIV patients, 9(69.2%) were male and 
4(30.7%) were female thus Hepatitis B were more common among male 
patients. 
 
Table 11: SEX DISTRIBUTION IN HBsAg POSITIVE HIV 
PATIENTS 
 
 
 
 
 
 
 
Figure 11: SEX DISTRIBUTION IN HBsAg POSITIVE HIV 
PATIENTS 
 
MALE FEMALE TOTAL 
9 4 13 
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SEX WISE AGE DISTRIBUTION IN HBsAg POSITIVE HIV     
PATIENTS 
 Out of 13 HBsAg positive HIV patients, the most common affected 
age group among males was 41-50 years with 4(30.7%) patients and in 
female was 20 to 30 years with 2(15.8%) patients. 
 
Table 12: SEX WISE AGE DISTRIBUTION IN  
HBsAg POSITIVE HIV PATIENTS 
 
AGE MALE FEMALE 
20-30 2 2 
31-40 1 0 
41-50 4 1 
51-60 1 1 
61-70 1 0 
71-80 0 0 
TOTAL 9 4 
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Figure 12: SEX WISE AGE DISTRIBUTION IN  
HBsAg POSITIVE HIV PATIENTS 
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ALCOHOLIC DISTRIBUTION IN HBsAg POSITIVE HIV 
PATIENTS 
 Out of 13 HBsAg positive HIV patients, 8 patients were alcoholics 
with maximum no of patients in the age group of 41-50 years with 
3(23%) patients.  
 
Table 13: ALCOHOLIC DISTRIBUTION IN  
HBsAg POSITIVE PATIENTS 
 
AGE n=13 
20-30 2 
31-40 1 
41-50 3 
51-60 1 
61-70 1 
71-80 0 
TOTAL 8 
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Figure 13 : ALCOHOLIC DISTRIBUTION IN   
HBsAg POSITIVE HIV PATIENTS 
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SMOKERS DISTRIBUTION IN HBsAg POSITIVE HIV 
PATIENTS 
 
 Out of 13 HBsAg positive HIV patients 8 patients were smokers 
with maximum no of patients in the age group of 20 to 30 years with 
2(25%) patients. 
 
Table 14: SMOKERS DISTRIBUTION IN  
HBsAg POSITIVE HIV PATIENTS 
 
AGE n=8 
20-30 2 
31-40 1 
41-50 2 
51-60 2 
61-70 1 
71-80 0 
TOTAL 8 
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Figure14: SMOKERS DISTRIBUTION IN HBsAg POSITIVE HIV 
PATIENTS 
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ELEVATED LIVER ENZYMES IN HBsAg POSITIVE HIV 
PATIENTS 
 Out of 13 HBsAg positive HIV patients, elevated liver enzymes 
were found in 3(23%) patients. All these 3 patients showed elevated 
SGPT  (with 60 IU, 76 IU, and 120 IU), SGOT (with 80 IU, 68 IU and 94 
IU) and alkaline phosphatase(with 133,140 and 166 IU)  and they  
belonged to 2nd, 3rd and 6th decade.  
 
Table 15: ELEVATED LIVER ENZYMES IN  
HBsAg POSITIVE PATIENTS 
 
  
AGE No of patients SGPT (0-40 IU) 
SGOT 
(0-45 IU) 
ALKP 
(30-120 IU) 
20-30 1 76 68 140 
31-40 1 120 94 166 
41-50 0 - - - 
51-60 1 - - - 
61-70 1 60 80 133 
71-80 0 - - - 
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Figure 15: ELEVATED LIVER ENZYMES IN  
HBsAg POSITIVE HIV PATIENTS 
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MARITAL STATUS IN HBsAg POSITIVE HIV PATIENTS 
 Out of 13 HBsAg positive HIV patients, married individuals were 
maximum in the age group of 20 -30 years with 4(30.7%) patients and 
41-50 years with 4(30.7%) patients. 
 
Table 16 : MARITAL STATUS IN HBsAg POSITIVE HIV 
PATIENTS 
 
AGE MALE FEMALE TOTAL 
20-30 2 2 4 
31-40 1 0 1 
41-50 3 1 4 
51-60 2 1 3 
61-70 1 0 1 
71-80 0 0 0 
TOTAL 9 4 13 
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Figure 16: MARITAL STATUS IN HBsAg POSITIVE HIV 
PATIENTS 
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LITERACY LEVEL IN HBsAg POSITIVE HIV PATIENTS 
 Out of 13 HBsAg positive HIV patients, 4 were illiterate and the 
highest level of literacy among others were upto primary school with 
5(38.4%) patients followed by high school with 4(30.7%) patients. 
 
Table 17: LITERACY LEVEL IN HBsAg POSITIVE HIV 
PATIENTS 
 
EDUCATION MALE FEMALE TOTAL 
Primary School 5 - 5 
High School 2 2 4 
Higher Secondary - - - 
Illiterate 2 2 4 
TOTAL 9 4 13 
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Figure 17: LITERACY LEVEL IN HBsAg POSITIVE HIV 
PATIENTS 
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OCCUPATION IN HBsAg POSITIVE HIV PATIENTS 
 Out of 13 HBsAg positive HIV patients, the most common 
occupation was manual labourer with 5(38.4%) patients.  
 
Table 18: OCCUPATION IN HBsAg POSITIVE HIV PATIENTS 
 
OCCUPATION NO OF PATIENTS 
Manual labourer 5 
Mason 1 
Auto driver 1 
Office worker 1 
Gold smith 1 
House wives 3 
Student 1 
TOTAL 13 
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Figure 18 :  OCCUPATION IN HBsAg POSITIVE HIV PATIENTS 
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CD4 COUNT IN HBsAg POSITIVE HIV PATIENTS 
 Out of 13 HBsAg positive HIV  patients, CD4 count was decreased 
in 3(3%) of patients. 
 
Table 19: CD4 COUNT IN HBsAg POSITIVE HIV PATIENTS 
 
CD4 COUNT NO OF PATIENTS 
Decreased 3 
Normal 96 
TOTAL 100 
 
 
Figure 19: CD4 COUNT IN HBsAg POSITIVE HIV PATIENTS 
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ASSOCIATED STI CONDITIONS  
 Associated STI conditions in our study included vulvovaginal 
candidiasis, bacterial vaginosis, genital wart, genital molluscum 
contagiosum,  candidial balanoposthitis,  genital ulcer disease   and  non 
specific urethritis. These associated STI conditions were more common in 
males in the age group of 31 to 40 years with 7(53.8%) patients. 
 
Table 20: ASSOCIATED STI CONDITIONS 
 
AGE MALE FEMALE TOTAL 
20-30 - 3 3 
31-40 3 4 7 
41-50 - - - 
51-60 1 - 1 
61-70 1 - 1 
71-80 - - - 
TOTAL 5 7 12 
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Figure 20 : ASSOCIATED STI CONDITIONS  
 
 
72 
 
 
 
ASSOCIATED CUTANEOUS FINDINGS IN HIV POSITIVE 
PATIENTS 
 The associated cutaneous conditions in our study included oral 
candidiasis(2%), tinea cruris(1%), seborrheic dermatitis(1%), herpes 
zoster(1%), borderline Hansen(1%). 
 
Table 21: ASSOCIATED CUTANEOUS FINDINGS IN  
HIV POSITIVE PATIENTS 
 
AGE NO  OF PATIENTS 
31-40 2 
41-50 2 
51-60 - 
61-70 1 
71-80 - 
TOTAL 5 
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Figure 21: ASSOCIATED CUTANEOUS FINDINGS  
IN HIV POSITIVE PATIENTS 
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PARTNER SCREENING IN HIV POSITIVE PATIENTS  
 Out of 78 married individuals in our study, 6(6%) patients partners 
were positive for HIV, 5(5%) patients partners were negative for 
HIV,3(3%) patients were widow and partners of 64 patients did not turn 
out for screening inspite of screening advice. 
 
Table 22 : PARTNER SCREENING IN  
HIV POSITIVE PATIENTS 
 
Partner screening status Screening Results 
6 positive 
5 negative 
- 3 patients were widows 
64 patients partner  did not turn out for screening 
 
 
Figure 22: PARTNER SCREENING IN HIV POSITIVE PATIENTS 
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HIGH RISK GROUPS AMONG HIV POSITVE PATIENTS 
 Out of 100 HIV infected patients, the major high risk groups were 
heterosexuals with 95(95%) patients followed by alcoholics 49(49%), 
smokers 48(48%), MSM 2(2%), bisexuals 2(2%), CSW 1(1%), and 
patients with blood transfusion1(1%). 
 
Table 23: HIGH RISK GROUPS AMONG HIV POSITVE 
PATIENTS 
 
HIGH RISK GROUPS NO OF PATIENTS 
Heterosexuals 95 
Alcoholics 49 
Smokers 48 
MSM 2 
Bisexuals 2 
CSW 1 
IV drug users 1 
Blood transfusion 1 
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Figure 23: HIGH RISK GROUPS AMONG  
HIV POSITVE PATIENTS 
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PREVALENCE OF SYPHILIS IN HIV POSITIVE PATIENTS  
 Prevalence of Syphilis in HIV positive patients in our study  was 
2(2%). Out of the two patients, one patient was VDRL reactive (1:16 
dilution) and the other patient was both VDRL reactive (1:260 dilution) 
and TPHA positive. 
 
Table 24: PREVALENCE OF SYPHILIS IN  
HIV POSITIVE PATIENTS 
 
Test Result No of Patients 
VDRL Reactive 1 
VDRL+TPHA Reactive 1 
 
 
Figure 24: PREVALENCE OF SYPHILIS IN HIV POSITIVE 
PATIENTS 
  
 
Discussion 
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DISCUSSION 
 
 In this study we included a total of 100 HIV positive patients 
attending STD clinic. Among these, in HIV positive patients the 
seroprevalence of Hepatitis B infection was 13(13%). 
 
 In a similar study conducted by Sandhya Sawat in Mumbai63  out of 
540 patients,  90(16.7%) patients were positive for Hepatitis B infection. 
 
 This is in contrast to a study conducted by Yitayih64 in Northwest 
Ethiopia in which the prevalence of Hepatitis B infection was 20(5.6%) 
patients out of 400 patients. 
 
 Whereas a study conducted in Slovenia65 in 2008 showed a high 
prevalence of Hepatitis B of about 25.5%74 and a study by Chiekulie66 
kevin Diwe in South East Nigeria showed a low prevalence of Hepatitis B 
of about 9(2.2%) patients out of 404 patients. 
 
 Thus comparing the above studies a significant  high prevalence of 
Hepatitis B infection was found in our study.  
 
 The seroprevalence of hepatitis C in our study out of 100 patients 
attending STD clinic was 1% in HIV positive patients, which was 
comparable to a study conducted by Guimaraes67 Nebenzal in which the 
79 
 
seroprevalence of Hepatitis C infection in HIV positive patients was 
4(0.9%) patients out of 431 patients. 
 
 In another study conducted by Sandhya Sawat and Sachee 
Agrawal63 the concomitant infection of Hepatitis C with HIV was 
7(1.3%) out of 540 patients which is very identical to our study. 
 
 Whereas a study conducted by Seme K, Lunar MM Slovenia65 
reported a high prevalence in comparison to our study of 10.7%  which 
can be attributed to the lack of effective vaccine and other treatment 
modalities against Hepatitis C infection. In a study done by Yitayih64 in 
the year 2011 which was conducted in a study population of about 400 
individuals reported 5% co-infection of Hepatitis C with HIV. 
 
 Thus the wide range of prevalence in Hepatitis B and Hepatitis C 
infection can be due to variation in individuals immunity, exposure to risk 
factor, variation in the geographic region, associated underlying disease 
and also due to different  routes of exposure to infection.75-78    
 
 The combined infection of Hepatitis B and Hepatitis C was 1% in 
our study which was similar to a study of 0.5% (1 out of 200 patients)  
conducted by Sumit Goyat68  and 0.9%(4 out of 431 patients)  conducted 
by Guimaraes.67 
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 Triple infection HIV, Hepatitis B, and   Hepatitis C in our study 
was 1% which was similar to a study done by Guimaraes67 which was 
conducted in the age group between 15 to 49 years in which 5 of them out 
of 431 i.e 1.2% patients showed triple infection of HIV, Hepatitis B, and   
Hepatitis C.  Another study done by Sandhya Sawat63 showed the 
concomitant infection of  HIV, Hepatitis B, and   Hepatitis C as 0.4% (2 
out of  540 patients) respectively. But a study done by Chiekulie66 kevin 
Diwe in South East Nigeria reported that no participants in his study had 
triple infection of HIV, Hepatitis B, and   Hepatitis C.   
 
 In our study the prevalence of Syphilis in HIV positive patient was 
2(2%) which was comparable to a study conducted by Guimaraes67 in 
which 2 individuals had Syphilis and HIV co-infection out of 431 patients 
(0.4%). 
 
 In another study conducted by Nancy crum-cianflone69 the 
prevalence of Syphilis in HIV positive patient was 6% (33 out of 600 
patients) which was relatively closer  to the studies conducted by 
Alemayehu A, Shimelis T85 and Bjekić M, Marković M86 which reported 
a prevalence of 9.8% and 15.3% respectively. 
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 In contrast to these studies a study conducted by D.T urbadkar70 
showed a high prevalence of 47% (42 patients out of 88 HIV seropositive 
cases). 
 
 Thus compared to the above studies a low prevalence of Syphilis in 
HIV positive patient was noticed in our study which is due to the 
effective antibiotic era at present. 
 
 In our study Liver enzyme level was elevated in 4(4%) HIV 
positive patients and 3(3%) of HIV-HbSAg positive patients. 
 
 Among these 4(4%)  HIV positive patients 3 patients showed 
elevated SGPT  (with 60 IU, 76 IU, and 120 IU), SGOT (with 80 IU, 68 
IU and 94 IU) and alkaline phosphatase(with 133,140 and 166 IU)  and 1 
patient showed isolated elevation of alkaline phosphatase(140 IU) with 
normal levels of SGPT and SGOT 
 
 Among the HIV-HbSAg positive patients all 3 patients showed 
elevated SGPT  (with 60 IU, 76 IU, and 120 IU), SGOT (with 80 IU, 68 
IU and 94 IU) and alkaline phosphatase (with 133,140 and 166 IU) levels.  
 
 Out of  the 3 liver enzymes there are literature reporting that 
alkaline phosphatase is most important and commonly associated liver  
enzyme in HIV positive patients104 .Where as SGPT is more commonly 
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associated with alcoholic liver disease. Similarly in a study conducted by 
Ranjit pateel showed that alkaline phosphatase was elevated in 35% 
above the normal limit in HIV positive patient and in another study 
conducted by Payne T H,72  showed a marked elevation of serum ALP in 
excess of 1000IU/L in 17% of AIDS patient.  
 
DEMOGRAPHIC CHARACTERS 
AGE 
 The most common age group involved in our study in HIV infected 
individuals were 31-40 years which was similar to a study conducted by 
Yitayih64 were the study participants were in the age group of  30-39years 
while 25- 35 years age group participants were common in a study 
conducted by Sandhya Sawat. 63 
 
SEX 
 Out of 100 patients HIV was more common among males with 
70(70%) patients while females were 30(30%) patients which was very 
much similar to a study conducted by Saravanan s Velu 73and Sumit 
Goyat68 with male preponderance of 73% and 65.5% but a study 
conducted by Chiekulie66 kevin Diwe showed a female preponderance 
with female 69.2% and male 30.8% patients respectively. 
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OCCUPATION  
 The study participants in our study were most of them who 
belonged to manual labourer occupation with 40 patients belonging to 
manual labour, followed by mason with 7 patients , auto driver with 5 
patients, electricians with 4 patients, truck driver with 3 patients and 
farmer with  2 patients and others belonged to mechanic, painter, hotel 
worker, gold smith, accountant and artist, apart from these there were 5 
students and 16 house wives, whereas a study conducted by Amar 
Surjushe74  among  the 40 male patients, 20 were manual laborers and 14 
were farmers, and among  the 20 female cases, 18 patients were 
housewives. In another study conducted by Chiekulie66 kevin Diwe   out 
of  404 patients commercial drivers constituted  about 7.6%, public 
servants 12.6%, students were about 10.5% and 69% belonged to farmers, 
traders and artisans.  
 
LITERACY 
 The highest level of formal education attained by our study 
participants were high school level with 33(33%) patients which was next 
followed by primary school level with 26(26%) and illiterate constituted 
about 34(34%) patients. 
 
 In a study conducted by Chiekulie66 kevin Diwe  there was a close 
similarity to our study with primary education level to 27.3%, secondary 
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education upto 55.3%  and 3.6% constituted illiterate and a study  
conducted by Yitayih64  showed HIV infected individuals with higher 
secondary education and diploma constituted to about 4(10.3%) patients . 
 
 Another study reported by Goyal Ankur and Goyal Sapna79 in a 
study group of 358 HIV infected patients showed that 89.1% were 
illiterate and below 8 th standard, whereas a   study in Brazil80 reported 
that 74% of the HIV cases educational level were illiterate or had hardly 
completed middle school.   
 
 Thus in our study the percentage of illiterate was slightly higher 
than educated individuals which stresses the need  to create awareness 
about the importance of education among these individuals since lack of 
education plays a vital role in the occurrence of  STIs . 
 
HIGH RISK GROUPS 
MSM 
 In our study a low prevalence of  MSM of about 2(2.8%) was 
noted out of 70 HIV infected male patients and no MSM were noticed in 
Hepatitis B and Hepatitis C  infected patients, and MSM in Syphilis was 
seen only in one patient. 
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 In a study conducted by Sumit Goyat68 the prevalence of  MSM in 
HIV infected  patients was 1% and the prevalence of  MSM in Hepatitis 
B infected patients was 1(11.11%) out of  9 patients and none of  
Hepatitis C infected patients was  MSM. 
 
 Whereas a study conducted by Saje A, Tomazic81 J in Syphilis 
patients showed relatively high prevalence of  MSM of about 76.3%, 
another study conducted by Taru Garg, Ram and Chander, Arpita Jain82 
showed prevalence as  75(11.4%)  patients out of  660  patients. 
 
HETEROSEXUALS 
 In our study majority of HIV infected patients were heterosexuals 
with 95(95%) patients and all the 13 Hepatitis B infected patients and one 
Hepatitis C infected patient were heterosexuals. In a study done by 
Sandhya Sawat63 showed that heterosexuals constituted 80.6% out of 540 
patients, whereas a study conducted by Sumit Goyat68 showed the 
heterosexuals rates as 72%, 66.7% and 53.3% in HIV, Hepatitis B, and   
Hepatitis C infected patients respectively. 
 
BISEXUALS 
 The prevalence of  bisexuals in our study was 2(2%)  patients in 
HIV infected individuals and none of these two patients had Hepatitis B 
and Hepatitis C infection  or Syphilis. Similarly in a study conducted by 
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Raj Narayan, and Deepak Mathur83 the prevalence of  bisexuals was 
2(2%) out of 100 patients.   In another study conducted by Sumit Goyat68 
prevalence of bisexuals was 1% among HIV infected patients. 
 
COMMERCIAL SEX WORKERS (CSW) 
 The prevalence of  commercial sex workers(CSW) in our study 
was 1(1%) among HIV infected patients but this patient did not have any 
co-infection with Hepatitis B, Hepatitis C or Syphilis, whereas in a study 
conducted by Raj Narayan, and Deepak Mathur83 reported the prevalence 
of  commercial sex workers(CSW) to be  28% in HIV infected patients 
and 40% in VDRL reactive patients, similarly in a study conducted by 
Paritosh Kumar Banerjee, and Manol Kumar Mandal84 the prevalence of  
commercial sex workers(CSW) was 3% in Calcutta and a study 
conducted in Mumbai reported 18% prevalence of  commercial sex 
workers(CSW). 
 
 Though a low prevalence of 1(1%) commercial sex workers (CSW) 
was reported in our study compared to a significantly high prevalence of 
18% in Mumbai but since commercial sex workers (CSW) form a vital 
reservoir of  many STIs their effective screening and timely intervention 
of treatment is important. 
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TRANSGENDERS    
 There was no history suggesting the occurrence of HIV 
seropositivity among Transgenders in our study however a study 
conducted by  Carobene M, Bolcic F, Farías MS89 among sex workers in 
Argentina showed the prevalence of  Transgenders in Hepatitis B with 
HIV co-infection as 3.2% and Hepatitis C with HIV co-infection as 6.5% 
respectively. In another study conducted by Fabiana Schuelter-Trevisol90 
in Brazil among 147 patients showed prevalence of  Transgenders as 
7(4.3%) patients.  
 
INTRAVENOUS DRUG USERS (I.V drug users) 
 In our study a single patient gave history of intravenous drug abuse 
who had HIV seropositivity but had no co-infection of Hepatitis B, 
Hepatitis C or Syphilis which was comparable to the study conducted by 
Sandhya Sawat1 which showed a prevalence of about 2(0.4%)  out of 540 
patients.  
 
 In a study conducted by Sumit Goyat68  showed a prevalence of  
2.5%, 22.2% and 20% in HIV, Hepatitis B, and  Hepatitis C infected 
patients whereas a study done by Raj Narayan, and Deepak Mathur83 
which was conducted in 100 patients had no patients with I.V drug users.  
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BLOOD TRANSFUSION 
 In our study only one patient out of 100 patients i.e 1% patient 
gave history of blood transfusion who had HIV seropositivity but had no 
co-infection of Hepatitis B, Hepatitis C or Syphilis which to some extent 
is similar to the study conducted by Sandhya Sawat63 where among a 
study group of 540 HIV infected patients 15(2.8%) patients had history of 
blood transfusion. In another study done by Sen et al87 showed about 
8.9% patients had received blood transfusion who were infected with 
HIV. Although prevalence of HIV infected patients who received blood 
transfusion is low in our study, there are study based evidence suggesting  
that through a single unit of blood transfusion there is about 1% chance of 
getting STI related problems,88 Hence  prompt screening of  blood donors  
are emphasized in order to decrease the occurrence blood transfusion 
related STIs. 
 
PERINATAL TRNSMISSION 
 Perinatal transmission is an important route for transmission of 
HIV other STIs. In our study though there was no history of perinatal 
transmission among the 25 married women. Similar to our study, a study 
conducted by Sandhya Sawat63 out of 540 HIV infected patients proved 
no history of perinatal transmission however a study conducted by Sumit 
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Goyat68 showed out of 200 patients, 4% women gave history of vertical 
transmission in HIV infected patients. 
 
ALCOHOLICS  
 Among the 70 male patients in our study 49(70%) patients were 
alcoholics with HIV seropositivity and the maximum number of patients 
belonged to 20-30 years with 15(21.4%) patients, this was comparable to 
a study conducted by Fabiana Schuelter-Trevisol90 in Brazil in which 
83.7% patients among 147 patients were alcoholics. 
  
 Out of 13 HBsAg positive patients 8(61.5%) patients were 
alcoholics with maximum no of patients in the age group of 41-50 years 
with 2(25%) patients and only one patient had anti-HCV antibodies who 
was an alcoholic. 
 
 Thus the prevalence of alcoholics in our study among HIV, 
Hepatitis B, and   Hepatitis C infected patients were 70%, 61.5% and 1% 
respectively and none of the VDRL reactive patients were alcoholics. 
This significant percentage of alcoholics is thus an important risk factor 
for STIs and associated with liver damage on chronic use.  
 
SMOKERS 
 Among the 70 male patients in our study  48(68.5%) patients were 
smokers with HIV seropositivity and the most commonly affected age 
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groups were 31-40years with 13(18.5%) patients and out of 13 HBsAg 
positive patients 8(61.5%) patients were smokers and the maximum no of 
patients belonged to  2nd, 4th and 5th decade with 2(25%)patients and none  
of the patients had anti-HCV antibodies or VDRL reactivity. Though 
smoking is not directly related to STIs chronic smoking is associated with 
various pulmonary complication and decreased immunity which in turn  
contributes to increased chance for the occurrence of STIs. 
 
CD4 COUNT 
 In our  study out of 13 HIV-HBV infected patients, 3 patients 
showed markedly decreased value of CD4 count (of 191, 160, 
170cells/mm3) and all these three patients were also chronic alcoholics 
which further contributes to liver damage. The mean CD4 count among 
these 13 patients was 268 which was very similar to a study conducted by 
Yitayih64 in which the mean CD4 count among 400 patients was 250 in 
contrast to a study conducted by Lodenyo H, Schoub B, Ally R, Kairu 
S91, and Olufemi A, Emmanuel A92 in which the mean CD4 count was 
141.6 and 121cells/mm3. The mean CD4 count in our study in HIV-HCV 
infected patients was 170cells/mm.3 
 
 Whereas a study conducted by Olufemi A, Emmanuel A92  and 
Tripathi A, Khanna M93 reported a mean CD4 count of 260 and 
288.6cells/mm3 respectively. The mean CD4 count in our study were 
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relatively lower in males when compared to females (258vs291) similar 
difference in gender were noticed in the studies conducted by Akinsegun,  
Adedoyin D94 and Tugume SB95 respectively. 
 
ASSOCIATED STI CONDITIONS 
 The occurrence of HIV, Hepatitis B, and   Hepatitis C and Syphilis 
increases the susceptibility of getting other STIs like in our study 12 
patients presented with a number of other viral, fungal and bacterial STIs 
like vulvovaginal candidiasis (4%), bacterial vaginosis (3%), genital 
wart1(1%), genital molluscum contagiosum 1(1%), candidial 
balanoposthitis1(1%), genital ulcer disease 1(1%) and non specific 
urethritis 1(1%) . 
 
 In a study done by Raj Narayan, and Deepak Mathur83 which was 
conducted in 100 patients showed associated conditions like   23(23%) 
cases of genital warts, 2(2%) cases of Non specific urethritis 
22(22%)cases of chancroid,15(15%)cases of genital herpes, 10(10%) 
cases of  balanoposthitis and  8(8%) cases of gonorrhea. 
 
ASSOCIATED CUTANEOUS CONDITIONS 
 Common dermatological conditions like oral candidiasis(2%), tinea 
cruris (1%), seborrheic dermatitis(1%), herpes zoster(1%), borderline 
Hansen(1%) were seen among 5 out of 100 patients, among these oral 
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candidiasis was the commonest cutaneous finding which was also a 
commoner cutaneous condition in a number of Indian studies.96,97,98,99 
 
 Similarly another study conducted by Shobhana A, Guha SK100 
showed various cutaneous conditions in HIV infected patients like oral 
candidiasis, dermatophytosis and gingivitis (13% each), herpes zoster 
(6%), herpes simplex, scabies (5% each), molluscum contagiosum, 
staphylococcal skin infections, oral herpetic lesions, Papular pruritic 
dermatoses and guttate psoriasis. A study conducted by Kar PK, 
Ramasastry CV101 showed a high prevalence of  herpes zoster of  
11(9.5%) out of 115 patients when compared to 1% in our study. 
Similarly tinea cruris was present in only 1% of our case compared to a 
very high prevalence of about 56.66% conducted by Amar Surjushe.102 
 
Summary 
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SUMMARY 
 In this study out of 100 HIV positive patients the prevalence of 
Hepatitis B was 13%, Hepatitis C was 1%, Syphilis was 2% and 
elevated liver enzymes was  reported in 4(4%) patients. 
 
DEMOGRAPHIC CHARACTERS 
AGE GROUP 
 The most common age group among HIV positive patients was 3rd 
decade with 33%.  
 The most common age group among HBV positive HIV patients was 
4th decade  with 38.6%. 
 The most common age group among HCV positive HIV patients was 
4th decade with 1% . 
 The most common age group among VDRL reactive patients was  3rd 
decade with 2%. 
 
SEX 
 In our study males were predominantly affected than females. 
  70%  were males and 30%  were females in HIV positive patients. 
 69.2% males and 30.7% females in HBV positive HIV patients. 
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 2% males in Syphilis and 1% males in HCV positive HIV patients 
were reported with no females affected. 
 
OCCUPATION 
 The most common occupation among HIV positive patients was 
manual labour (31%)  in males followed by masons (7%), auto drivers 
(5%) and truck drivers(3%) and females were predominantly house 
wives (16%)  followed by manual labourers (9%). 
 The predominant occupation among HBV positive HIV  patients was 
manual labour (5%) in males and females (4%). 
 Similarly manual labourers was the predominant occupation in HCV 
positive and VDRL reactive patients with 1% and 2% respectively. 
 
LITERACY 
 The highest education level among  HIV positive patients was upto 
high school with 33( 33%) patients. 
 The highest education level among  HBV positive HIV patients was 
upto primary school with 5(38.4%) patients. 
 The highest education level among  HCV positive HIV patients was 
upto primary school with 1(1%) patients. 
 The highest education level among VDRL reactive patients were upto 
primary school with 1(1%) patients. 
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HIGH RISK GROUPS 
a)   MSM 
 Prevalence of  MSM was 2(2.8%) patients out of 70 HIV positive 
male patients. 
 No MSM was noticed in Hepatitis B and Hepatitis C infected patients.  
 MSM in Syphilis was seen only in one patient. 
 
b)    HETEROSEXUALS 
 In our study prevalence of heterosexuals in HIV positive patients was 
95(95%) patients.  
 Prevalence of heterosexuals in HBV and HCV positive HIV patients 
was 13(100%) patients and 1(100%) patients respectively. 
 Prevalence of heterosexuals in VDRL reactive HIV patients was 
1(50%) patients. 
 
c) BISEXUALS 
 The prevalence of bisexuals among HIV positive patients was 2(2%)  
patients . 
 None of the HBV, HCV positive HIV patients and VDRL HIV 
reactive patients were bisexuals. 
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d) COMMERCIAL SEX WORKERS(CSW) 
 The prevalence of  commercial sex workers(CSW) in our study was 
1(1%) among HIV infected patients. 
 No commercial sex workers (CSW) were reported among the HBV, 
HCV positive and VDRL reactive  HIV  patients. 
 
e) INTRAVENOUS DRUG USERS(I.V drug users) 
 The prevalence of  I.V drug users  among  HIV positive patients was 
1(1%). 
 None of the HBV, HCV positive HIV patients  or VDRL reactive HIV 
cases were reported among  I.V drug users. 
 
f) BLOOD TRANSFUSION 
 1(1%) patient gave history of blood transfusion among HIV positive 
patients with no case reported among HBV, HCV positive HIV 
patients or VDRL reactive  HIV  patients. 
 
g)  ALCOHOLICS 
 Prevalence of alcoholics in our study among HIV, HBV, and   HCV 
positive patients were 70%, 61.5% and 1% respectively and none of 
the VDRL reactive HIV patients were alcoholics. 
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h) SMOKERS 
 Prevalence of smokers were 48(68.5%) patients in HIV positive 
patients  and 8(61.5%) patients in HBV positive HIV patients no 
smokers were reported in HCV positive HIV patients  or VDRL 
reactive HIV patients. 
 
i) ASSOCIATED STI CONDITIONS 
 The associated STI conditions in our study included vulvovaginal 
candidiasis (4%), bacterial vaginosis(3%), genital wart 1(1%), genital 
molluscum contagiosum 1(1%), candidial balanoposthitis1(1%), 
genital ulcer disease 1(1%) and non specific urethritis 1(1%) . 
  
j) ASSOCIATED  CUTANEOUS  CONDITIONS 
 The associated cutaneous conditions in our study included oral 
candidiasis(2%), tinea cruris(1%), seborrheic dermatitis(1%), herpes 
zoster(1%), borderline Hansen(1%). 
 
k) CD4 COUNT 
 CD4 count was decreased among 3(23%) HBV positive HIV patients 
and 1(1%)  HCV positive HIV patients.  
Conclusion 
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CONCLUSION 
 In our study group of 100 HIV positive patients, the prevalence of 
Hepatitis B was 13%, Hepatitis C was 1%, Syphilis was 2% and 
elevated Liver Enzymes was 4% . 
 Most common affected age group was 3rd and 4th decade. 
 Males were predominantly affected than females. 
 Most common occupation among males was manual labour, whereas 
females were predominantly house wives. 
 The highest level of education was upto high school and primary 
school and the literacy level among males was comparatively higher 
than females. 
 The major High Risk Group was heterosexuals followed by 
alcoholics, smokers, MSM, bisexuals , CSW, and patients with blood 
transfusion. 
 Associated STI conditions included vulvovaginal candidiasis, bacterial 
vaginosis, genital wart, genital molluscum contagiosum, candidial 
balanoposthitis, genital ulcer disease and non specific urethritis.    
 Associated cutaneous  conditions  included oral candidiasis, tinea 
cruris, seborrheic dermatitis, herpes zoster, and borderline Hansen. 
 CD4 count was markedly decreased in 3 patients. 
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 Thus to conclude in our study,   
1) HIV-HBV co-infection was seen in 13(13%) patients. 
2) HIV-HCV co-infection was seen in 1(1%) patient.  
3) HIV with Syphilis co-infection was seen in 2(2%) patients. 
4)  Elevated liver enzyme levels in HIV positive patients were seen in 
4(4%) patients. 
5) Decreased CD4 count was seen seen in 3(3%) patients. 
6) HIV-HBV co-infection with elevated liver enzyme levels and 
decreased CD4 count was seen in 3(3%) patients. 
7) HIV-HCV co-infection with elevated liver enzyme levels and 
decreased CD4 count was seen in 1(1%) patient. 
8) HIV-HBV-HCV co-infection with elevated liver enzyme levels and 
decreased CD4 count was seen in 1(1%) patient. 
 
 The decreased CD4 count with elevated liver enzyme levels as 
seen in our study will cause further liver damage, hence ART should be 
immediately started in these patients. However according to WHO 
guidelines41 patients with combined HIV-HBV or HIV-HCV infection 
should be started on ART irrespective of the CD4 count. 
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 Hence routine screening for Hepatitis B and Hepatitis C should be 
emphasized in HIV positive patients since its early detection can decrease 
the morbidity and mortality due to liver damage among these patients.  
 
 Routine screening for Syphilis should also be encouraged in HIV 
positive patients since its early detection can decrease the morbidity and 
mortality among these patients. 
 
 By  routine screening effective treatment can be implemented to 
increase the life span and quality of life among such patients . 
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Annexures 
  
ABBREVIATIONS USED 
 
1. HIV    : Human Immunodeficiency Virus 
2. HART   : Highly active Antiretroviral Theraphy 
3. MSM   : Men having Sex with Men 
4. VDRL   : Venereal Disease Research Laboratory 
5. HBV   : Hepatitis B Virus 
6. HCV   :  Hepatitis C Virus 
7. HBsAg   : Hepatitis B surface antigen 
8. HBeAg   : Hepatitis B envelope antigen 
9. Anti-HBsAb  :  Hepatitis B surface antibody 
10. Anti-HBcAb  : Hepatitis B core antibody 
11. PCR    : Polymerase Chain Reaction 
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1 Senthil 25 male UM 10th mason A+S - - - - 17 10 75 - -- NR 
2 Karthik 27 male M 10th electrician A - - - - 68 27 75 - - NR 
3 Suraj 45 male M 10th clerk A - - - - 14 12 70 - - NR 
4 Prabhu 25 male M 8th manual labourer S - - - - 16 24 72 - - NR 
5 Deva 38 male M - mechanic A+S - - - - 27 24 60 -  NR 6 Allimuthu 30 male M 7th manual labourer A+S - positive - - 18 20 41 - BL leprosy NR 
7 Surrulivel 60 male M 4th manual labourer A+S - - - - 28 26 47 - - NR 
8 Selvaraj 63 male M - manual labourer A+S - positive - - 60 80 92 - candidiasis NR 
9 Yesudev 38 male M - manual labourer A+S negative - - - 28 18 64 -  NR 
10 Veeran 33 male M 10th accountant A+S+IVD - - - - 30 34 64 - candidiasis NR 
11 Ganesh 28 male M - mason A+S - - - - 76 68 133 - - NR 
12 Raju 75 male UM - mason A+S - - - - 23 14 41 - - NR 
13 Babu 39 male M 6th manual labourer A+S - - - - 14 68 47 - HZ NR 
14 Murugan 50 male M 7th manual labourer A+S - positive - - 24 26 40 - - NR 
15 Thirupathy 32 male M 6th mason - - - - - 14 17 47 - - NR 
16 Gopi 44 male M 8th manual labourer S - - - - 17 13 43 - - NR 
17 Boobalan 47 male M 10th auto driver - - - - - 18 12 49 - - NR 
18 Mani 63 male M -- manual labourer S - - - - 34 24 41 - - NR 
19 Pandiyan 35 male M 2nd electrician S - - - - 24 38 42 - - NR 
20 Jagan 24 male M 10th auto driver S - - -- - 16 20 33 - - NR 
21 Susendran 42 male M 10th farmer S - positive - - 19 20 26 - - NR 
22 Senthil 28 male M 5th mason S - - - - 15 26 30 - - NR 
23 Sivakumar 39 male M 8th auto driver A - - - - 19 20 26 genital wart - NR 
24 Bakiyaraj 34 male UM - manual labourer - - - - - 14 17 47 - - NR 
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25 Venkateshan 52 male M - manual labourer MBT - - - - 25 26 30 - - NR 
26 Mohan 53 male M 8th office worker - - positive - - 51 64 140 
candidial 
balanopost
hitis 
- NR 
27 Ezhil 45 male M 10th manual labourer S - - - - 33 24 30 - - NR 
28 Subbaiah 55 male UM - manual labourer A+S - - - - 26 16 46 - - NR 
29 Marimuthu 48 male M 12th mason A+S - - - - 19 33 38 - - NR 
30 Vasudevan 47 male M 8th electrician A - - - - 22 16 80 - - NR 
31 Murali 39 male M 7th manual labourer A+S - positive - - 120 94 
14
0 - - NR 
32 Raja 31 male M 11th electrician A+S - - - - 24 34 46 - - NR 
33 Michel 26 male M 12th manual labourer A+S - - - - 16 20 39 - - NR 
34 Chakravathy 29 male M 10th auto driver A+S - - - - 10 20 39 - T.cruris+SD NR 
35 Mani 24 male M 8th auto driver A+S - positive - - 50 21 64 - - NR 
36 Harinathan 32 male M - manual labourer - - - - - 26 20 41 MC left scrotum - NR 
37 Saravanan 44 male M 7th manual labourer A+S - - - - 21 17 20 - - NR 
38 Poncilla 69 male M 10th security A+S positive - - - 18 13 39 - - NR 
39 Gnanaraj 31 male M 8th security A - - - - 17 39 48 - - NR 
40 Vadivel 37 male M 6th manual labourer A+S - - - - 18 20 41 - - NR 
41 Muthu 48 male M - farmer A+S - - - - 21 28 60 - - NR 
42 Balwir 53 male M 9th pvt company A+S - - - - 18 13 39 - - NR 
43 Nagabushan 46 male M 10th real estate A+S - - - - 17 38 49 - - NR 
44 Shankar 50 male M 6th auto driver - positive - - - 18 20 41 - - NR 
45 Nataraj 40 male M 6th manual labourer A+S - - - - 28 18 44 - - NR 
46 Vetriselvan 43 male M 10th truck driver S negative - - - 16 20 63 - - NR 
47 Krishnan 44 male M 12th artist S - - - - 19 20 26 - - NR 
48 Veeramani 26 male UM - manual labourer S - - - - 25 26 30 - - NR 
49 Mohammed 28 male M 10th pvt company A+S negative - - - 11 14 26 - - NR 
50 Rupkumar 46 male M 4th gold smith A+S - positive - - 16 20 63 - - NR 
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51 Marimuthu 28 male UM 8th manual labourer A+S - - - - 18 20 39 - - NR 
52 Prabhakar 26 male UM 10th pvt company S - - - - 14 19 48 - - NR 
53 Irudhayaraj 42 male M 7th manual labourer A - positive positive - 28 18 94 - - NR 
54 Vijay 47 male UM - manual labourer A+S - - - - 19 22 74 - - NR 
55 Rajan 35 male UM - manual labourer A+S expired - - - 12 16 51 - - NR 
56 Chinivar 35 male M 5th manual labourer A - - - - 25 28 49 - - NR 
57 Ravi 55 male M - mason A+S expired positive - - 17 13 43 - - NR 
58 Ponraj 27 male UM 12th pvt company A - - - - 31 40 48 - - NR 
59 Babu 35 male M 12th clerk A negative - - - 23 41 46 - - NR 
60 Rayar 39 male UM 9th manual labourer A+S - - - - 14 23 41 - - NR 
61 Ram 37 male UM - manual labourer A+S - - - - 18 40 58 - - NR 
62 Ettaiyan 80 male M 7th manual labourer A expired - - - 28 14 40 - - NR 
63 Soundhar 24 male UM 5th manual labourer A - - - - 16 19 31 - - NR 
64 Babu 41 male M 12th pvt company A - - - - 13 18 55 - - NR 
65 Abilash 39 male M 7th hotel work A+S+B - - - - 20 27 38 - - NR 
66 Siva 43 male M - manual labourer A+S - - - - 25 13 46 - - NR 
67 Munusamy 64 male M 10th driver A+S+B - - - - 14 20 62 NSU+ phimosis  NR 
68 Somesh 33 male UM - painter A+MSM - - - - 18 20 39 - - NR 
69 Vairavan 32 male UM 7th manual labourer MSM - - - positive 17 39 46 GUD - R 
70 Jeeva 30 male UM - manual labourer - - - - positive 16 14 40 - - R 
71 Malliga 48 female M 8th house wife - - positive - - 21 33 63 - - NR 
72 Tamilarasi 41 female M - house wife - - - - - 16 20 65 - - NR 
73 Sundari 45 female M 4th house wife - expired - - - 18 24 40 - - NR 
74 Shantha 52 female M 2nd house wife - negative - - - 25 26 30 - - NR 
75 Selvi 47 female M - manual labourer - expired - - - 16 30 64 - - NR 
76 Monica 20 female UM 12th student - - - - - 11 13 38 - - NR 
77 Nageshwari 39 female M 10th student - - - - - 19 14 48 VVC - NR 
78 Venktama 24 female UM - student - - - - - 25 28 49 - - NR 
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79 Banu 29 female M - house wife CSW - - - - 14 12 51 - - NR 
80 Palaniammal 60 female M - manual labourer - - - - - 28 39 64 - - NR 
81 Suguna 35 female M 7th house wife - positive - - - 13 17 43 - - NR 
82 Mariyamma 37 female M - house wife - - - - - 26 33 63 - - NR 
83 Geetha 28 female M - house wife - - - - - 24 16 40 - - NR 
84 Alamelu 30 female M - house wife - - - - - 28 38 44 - - NR 
85 Divya 23 female UM 10th student - - - - - 31 40 60 BV - NR 
86 Najima 35 female M - house wife - - - - - 16 20 42 - - NR 
87 Girija 25 female M - manual labourer - - - - - 19 20 46 - - NR 
88 Jaya 52 female M 9th house wife - - - - - 21 24 80 - - NR 
89 Kala 34 female M 8th house wife - - - - - 19 14 41 - - NR 
90 Raji 20 female UM 10th student - - positive - - 28 19 40 - - NR 
91 Lakshmi 55 female M - house wife - expired positive - - 19 22 24 - - NR 
92 Gomathy 25 female M - manual labourer - - - - - 28 19 40 VVC - NR 
93 Rajkumari 32 female M 6th manual labourer - - - - - 19 22 24 BV - NR 
94 Jothi 35 female M 5th house wife - positive - - - 16 20 39 VVC - NR 
95 Valli 32 female M 8th house wife - - - - - 30 34 48 VVC - NR 
96 Lakshmi 37 female M - manual labourer - - - - - 18 13 39 - - NR 
97 Lalitha 27 female M - manual labourer - - - - - 17 29 46 BV - NR 
98 Ponnu 47 female M - house wife - - - - - 18 20 41 - - NR 
99 Sathya 33 female UM - manual labourer - - - - - 11 17 36 - - NR 
100 Bakiyam 35 female UM - manual labourer - - - - - 25 28 48 - - NR 
KEY FOR MASTER CHART  
 
1. SL.NO    -   Serial number 
 
2. HRG    -   High Risk Group 
 
3. HIV+HBV positive  - Human Immunodeficiency Virus+  
     Hepatitis B Virus positive patients  
 
4. HIV+HCV positive - Human Immunodeficiency Virus+  
     Hepatitis C Virus positive patients  
 
5. HIV+VDRL positive  - Human Immunodeficiency Virus+  
     Venereal Disease Research Laboratory
     test positive patients 
 
6. SGOT    - Serum glutamic oxaloacetic acid  
7. SGPT    - Serum glutamic pyruvate transaminase 
8. ALP    - Alkaline Phosphatase 
9. UM    - Unmarried 
10.  M    - Married 
11.  Pvt company  - Private Company 
12.  A+S    - Alcholic + smoker 
13. A+S+B   - Alcholic + smoker + blood transfusion 
14. MBT    - Multiple Blood Transfusion  
15. R    - Reactive 
16. NR    - Non-Reactive 
17. BL Leprosy   - Borderline Lepromatous Leprosy 
18. HZ    - Herpes Zoster 
19. T.cruris   - Tinea Cruris 
20. SD    - Seborhic Dermatitis 
21. NSU    - Non Specific Urethritis 
22. GUD    - Genital Ulcer Disease 
23. CSW    - Commercial Sex Workers 
24. BV    - Bacterial Vaginosis 
25. VVC    - Vulvo Vaginal Candidiasis 
26. MC    - Molluscum Contagiosum 
27. L scrotum   - Left Scrotum 
PROFORMA 
Name: 
Age/ Sex: 
Occupation: 
Address: 
 
OP no/ Patient ID no: 
Complaints: 
H/o present illness: 
H/o vaginal / urethral discharge: 
H/o abdominal pain: 
H/o dyspareunia: 
Menstrual history: 
Marital History: Single/ married/ divorced/ widow/ widower 
Living together or alone: 
Sexual history: 
Last marital contact: 
Premarital contact: 
Extra marital contact: 
Previous STI infections / treatments: 
 
 
Obstetric history: 
 
Past History: 
Tuberculosis: 
Diabetes: 
Hypertension: 
Bronchial asthma: 
Previous surgeries: 
Blood transfusions: 
Jaundice: 
 
Family History: 
 
Personal History: 
IV drug abuse/Smoker/alcoholic  
Aberrant sexual practice 
 
General examination: 
Built: 
Pallor: 
Jaundice: 
Pedal edema: 
Generalised lymphadenopathy: 
Pulse: 
BP: 
Systemic examination: 
CVS: 
RS: 
Abdomen: 
CNS: 
 
Local examination: 
Female: 
Any significant inguinal lymphadenopathy: 
Inspection: 
Vaginal discharge: 
Any genital abnormalities: 
Per vaginal examination : Position of cervix and uterus 
                                           Cervical motion tenderness 
Per speculum examination : Cervical discharge 
                                          Cervical erosion 
Skin: 
Mucosa: 
Bones and Joints: 
 
Male: 
Inguinal lymphadenopathy: 
Circumcised/ uncircumcised: 
Phimosis: 
Urethral discharge: 
Subprepucial discharge: 
Glans penis: 
Testis/ scrotum:  
Any ulcer/ erosion/ scars: 
Skin: 
Mucosa:  
Bones and Joints: 
 
Investigations 
Urine routine: 
Urethral/ vaginal / cervical discharge : Grams stain/ wet mount with normal 
saline   
 and KOH                                                            
Ulcers/erosions: Tzanck smear/ Dark field microscopy/ Grams stain 
Urine/ pharyngeal swab/ cervical culture for gonococci 
Rapid assay test for HIV 1 and 2 
VDRL test for syphilis 
HBsAg for Hepatitis B 
Anti-HCV antibody for Hepatitis C 
Liver Function Tests to study the enzymes levels  
Diagnosis: 
Clinical: 
Microbiologic 
 INFORMATION SHEET 
 
 Your specimen (Blood) has been accepted. 
 We are conducting a study on HIV detection among patients attending Rajiv 
Gandhi Government General Hospital, Chennai and for that your specimen 
(blood) may be valuable to us. 
 The purpose of this study is to diagnose early cases of HIV infection with the help 
of certain special tests. 
 We are selecting certain cases and if your specimen is found eligible, we may be 
using your specimen to perform extra tests and special studies which in any way 
do not affect your final report or management. 
 The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result in 
any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study 
period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
 
Signature of investigator                                                        Signature of participant 
 
Date: 
PATIENT CONSENT FORM 
 
Title of the study : “SEROPREVALENCE OF HEPATITIS B, HEPATITIS C & 
SYPHILIS AND LIVER ENZYMES LEVELS IN HIV POSITIVE PATIENTS 
ATTENDING STD CLINIC”   
 
Name of the participant : 
 
Name of the principal investigator: Dr. Sunitha .N 
 
Name of the Institution  :  Institute of Venereology,  
     Madras Medical College &  
     Rajiv Gandhi Government General Hospital,  
     Chennai – 3. 
 
 Documentation of the informed consent:  
I  ---------------------- have read the information in this form (or it has been read to 
me). I was free to ask any questions and they have been answered. I am over 18 years 
of age and exercising my free power of choice, hereby consent to be included as a 
participant in the study. 
1. I have read and understood this consent form and the information provided to me 
2. I have had the consent document explained to me 
3. I have been explained about the nature of the study 
4. My rights and responsibilities have been explained to me by the investigator 
5. I agree to co operate with the investigator and I will inform him/her immediately if 
I suffer unusual symptoms 
6. I have not participated in any research study at any time 
7. I am unaware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in this hospital 
8. I hereby give permission to the investigator to release the information obtained 
from me as a result of participation in this study to the sponsors, regulatory 
authorities, Government agencies and institutional ethics committee. I understand that 
they are publicly presented. 
9. My identity will be kept confidential if my data are publicly presented 
10. I am aware that if I have any question during the study, I should contact at one of 
the addresses listed above. By signing this consent form I attest that the information 
given in this document has been clearly explained to me and apparently understood by 
me, I will b given a copy of this consent document.  
 
 
 
Participant initials: 
 
For adult participants: 
 
Name and signature/ thumb impression of the participant (or legal representative if 
participant incompetent) 
 
_______________________             __________________                  ____________ 
Name                           Signature                                       Date 
 
 
Name and signature of impartial witness (required for illiterate patients): 
 
 
_______________________             __________________                  ____________ 
Name                           Signature                                       Date 
 
 
Address and contact number of the impartial witnesss : 
 
 
 
 
Name and signature of the investigator or his representative obtaining consent:  
 
 
_______________________             __________________                  ____________ 
Name                           Signature                                       Date 
 
 

 
